J. E. Ansell, B. E. Laulicht, S. H. Bakhru, M. Hoffman, S. S. Steiner et al., Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin, Thrombosis Research, vol.146, pp.113-118, 2016.

T. Bakchoul, H. Zollner, J. Amiral, S. Panzer, S. Selleng et al., Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis, Blood, vol.121, pp.2821-2827, 2013.

A. Bel, W. Borik, S. Davidson, J. Helies, L. Stimmer et al., Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons, European Journal of Cardio-Thoracic Surgery, vol.49, pp.682-689, 2016.

E. P. Bianchini, J. Fazavana, V. Picard, and D. Borgel, Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives, Blood, vol.117, pp.2054-2060, 2011.

Y. Bourti, J. Fazavana, M. Armand, F. Saller, D. Lasne et al., Inactivated antithrombins as fondaparinux antidotes: a promising alternative to haemostatic agents as assessed in vitro in a thrombin-generation assay, Thrombosis and Haemostasis, vol.116, pp.452-460, 2016.

J. Butterworth, Y. A. Lin, R. C. Prielipp, J. Bennett, J. W. Hammon et al., Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass, The Annals of Thoracic Surgery, vol.74, pp.1589-1595, 2002.

A. J. Chu, Z. G. Wang, M. Raicu, S. Beydoun, and N. Ramos, Protamine inhibits tissue factor-initiated extrinsic coagulation, British Journal of Haematology, vol.115, pp.392-399, 2001.

D. J. Cushing, W. D. Cooper, M. L. Cohen, J. R. Mcvoy, M. Sobel et al., Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist, European Journal of Pharmacology, vol.635, pp.165-170, 2010.

L. Demma and J. H. Levy, A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass, Anesthesia and Analgesia, vol.115, pp.1273-1278, 2012.

P. Gueret, S. Combe, C. Krezel, E. Fuseau, P. L. Van-giersbergen et al., First in man study of EP217609, a new long-acting, neutralisable parenteral antithrombotic with a dual mechanism of action, European Journal of Clinical Pharmacology, vol.72, pp.1041-1050, 2016.

J. Hirsh, K. A. Bauer, M. B. Donati, M. Gould, M. M. Samama et al., Chest, vol.133, pp.141-159, 2008.

J. C. Horrow, Protamine: a review of its toxicity, Anesthesia and Analgesia, vol.64, pp.348-361, 1985.

B. Kalaska, K. Kaminski, J. Miklosz, S. Yusa, E. Sokolowska et al., Heparinbinding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice, Translational Research, vol.177, p.10, 2016.

G. Lebreton, F. Tamion, J. Bessou, and F. Doguet, Cardiopulmonary bypass model in the rat: a new minimal invasive model with a low flow volume. Interactive Cardiovascular and Thoracic Surgery, vol.14, pp.642-644, 2012.

G. Lu, F. R. Deguzman, S. J. Hollenbach, M. J. Karbarz, K. Abe et al., A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nature Medicine, vol.19, pp.446-451, 2013.

M. I. Meesters, D. Veerhoek, F. De-lange, J. De-vries, J. R. De-jong et al., Effect of high or low protamine dosing on postoperative bleeding following heparin anticoagulation in cardiac surgery. A randomised clinical trial, vol.116, pp.251-261, 2016.

F. Ni-ainle, R. J. Preston, P. V. Jenkins, H. J. Nel, J. A. Johnson et al., Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation, Blood, vol.114, pp.1658-1665, 2009.

S. T. Olson, R. Swanson, and M. Petitou, Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa, Blood, vol.119, pp.2187-2195, 2012.

L. Rauova, L. Zhai, M. A. Kowalska, G. M. Arepally, D. B. Cines et al., Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications, Blood, vol.107, pp.2346-2353, 2006.

R. A. Shenoi, M. T. Kalathottukaren, R. J. Travers, B. F. Lai, A. L. Creagh et al., Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants, Science Translational Medicine, vol.6, pp.260-150, 2014.

E. Sokolowska, B. Kalaska, J. Miklosz, and A. Mogielnicki, The toxicology of heparin reversal with protamine: past, present and future, Expert Opinion on Drug Metabolism & Toxicology, vol.12, pp.897-909, 2016.